In a recent article published in the Journal of Nanobiotechnology, researchers presented a comprehensive study on the development and evaluation of curcumin-loaded nanoparticles, specifically Cur@PC-HA/CeO2 nanoparticles. The study focused on the synthesis of hyaluronic acid (HA) and cerium oxide (CeO2) nanoparticles to enhance the therapeutic efficacy of curcumin in treating various diseases, particularly those related to inflammation and cancer.
Image Credit: Kateryna Kon/Shutterstock.com
Background
Curcumin, a bioactive compound derived from turmeric, has shown significant potential in medical applications due to its anti-inflammatory and antioxidant properties. However, its clinical use is limited by poor solubility, rapid metabolism, and low bioavailability.
The researchers aimed to address these challenges by encapsulating curcumin in nanoparticles that could improve its delivery and release profile, particularly in the gastrointestinal (GI) tract, where it can exert its therapeutic effects more effectively.
The study reviews various types of nanoparticles, including polymeric nanoparticles, liposomes, and inorganic nanoparticles, emphasizing the advantages of hybrid systems that combine different materials to optimize drug delivery. The authors also review previous studies on curcumin-loaded nanoparticles, noting the need for improved formulations that can provide sustained release and targeted action in the colon.
The Current Study
The study details the synthesis of HA/CeO2 nanoparticles and the encapsulation of curcumin within these nanoparticles. The HA/CeO2 nanoparticles were synthesized using a precipitation method, where cerium salts were added to a HA solution in the presence of concentrated ammonia.
The resulting nanoparticles were then dialyzed and washed to remove unreacted materials. For curcumin loading, curcumin was dissolved in a dichloromethane-methanol co-solvent and mixed with a polyvinyl alcohol (PVA) solution. The mixture was sonicated to form nanoparticles, which were collected through centrifugation and washed.
The encapsulation and loading efficiencies of curcumin were assessed using fluorescence spectroscopy, measuring the free drug content in the supernatant after centrifugation. In vitro drug release studies were conducted to evaluate the release profile of curcumin in simulated gastrointestinal fluids, mimicking human digestive conditions.
Results and Discussion
The results of this study demonstrated the successful synthesis and characterization of hyaluronic acid (HA) and cerium oxide (CeO2) nanoparticles loaded with curcumin (Cur@PC-HA/CeO2 NPs). The synthesized nanoparticles exhibited a uniform size distribution, as confirmed by dynamic light scattering (DLS) analysis, which indicated an average hydrodynamic diameter of approximately 150 nm. This size is optimal for enhancing cellular uptake and ensuring effective delivery to inflamed tissues, particularly in the context of inflammatory bowel disease (IBD).
Transmission electron microscopy (TEM) images further corroborated the DLS findings, revealing spherical nanoparticles with a smooth surface morphology. The elemental composition of the nanoparticles was analyzed using energy-dispersive X-ray spectroscopy (EDX), confirming the presence of cerium, oxygen, and carbon, which are indicative of the successful incorporation of CeO2 and HA into the nanoparticle structure. Zeta potential measurements showed a negative surface charge, which is beneficial for stability in physiological conditions and enhancing interactions with positively charged cell membranes.
The encapsulation efficiency of curcumin within the nanoparticles was approximately 85 %, indicating a high loading capacity essential for therapeutic applications. In vitro release studies in simulated GI fluids demonstrated a sustained release profile of curcumin over 48 hours, with an initial burst release followed by a gradual release phase. This release pattern is advantageous for targeting localized inflammation in the colon, as it allows for prolonged exposure of curcumin to the inflamed tissues.
The therapeutic potential of Cur@PC-HA/CeO2 NPs was evaluated in a murine model of colitis. Following oral administration, the nanoparticles accumulated significantly at the site of inflammation, as evidenced by computed tomography (CT) imaging. The CT enhancement persisted for 24 hours, indicating effective targeting and retention of the nanoparticles in the inflamed colon. Treatment with curcumin-loaded nanoparticles resulted in a marked reduction in clinical symptoms and inflammatory markers, demonstrating their efficacy in alleviating colitis symptoms.
Conclusion
This study successfully demonstrates the synthesis and characterization of curcumin-loaded HA/CeO2 nanoparticles, highlighting their potential as an effective drug delivery system for curcumin. The findings suggest that these nanoparticles can significantly improve the solubility, stability, and bioavailability of curcumin, addressing limitations associated with its clinical use. The controlled release profile observed in simulated gastrointestinal conditions indicates that the nanoparticles could be particularly beneficial for targeting diseases of the GI tract.
The authors suggest that further in vivo studies are warranted to validate the therapeutic efficacy of these nanoparticles in clinical settings. Overall, this research contributes valuable insights into nanobiotechnology and opens new avenues for developing advanced drug delivery systems to enhance the therapeutic potential of natural compounds like curcumin.
Journal Reference
Cao L., et al. (2024). Oral enzyme-responsive nanoprobes for targeted theranostics of inflammatory bowel disease. Journal of Nanobiotechnology. DOI: 10.1186/s12951-024-02749-1, https://link.springer.com/article/10.1186/s12951-024-02749-1